After each treatment you administer to treat hyperpigmentation, we recommend that you prescribe or sell your patient TXA Anti-Spot Concentrate. This product uses the same formula as TXA NIA 5.10 Sterile Transepidermal Concentrate, but in a non-sterile version with a texture suitable for topical application at home. Studies clearly show that applying this formula after any hyperpigmentation treatment significantly reduces the risk of rebound effect.

For this type of problem, laser is the most effective method. However, the rebound effect and risk of post-inflammatory hyperpigmentation are notable. The topical application of tranexamic acid after laser sessions is an effective solution to avoid these undesirable effects.

We therefore recommend you use:

• TXA NIA 5.10 Concentré Stérile Transépidermique during your proceduresT
• XA FE AL 5.2.8 Topique HPI Prévention to be applied by the patient at home between each laser sessionTXA
• Anti-Spot Concentrate to be applied daily by the patient after the end of the procedure.

To maintain the sterility of the solution, we recommend that you use the vial as follows: remove the white plastic cap and insert a needle into the center of the grey stopper. You can then store the vial in a cool place, but be sure to use the product within 24 to 48 hours.

It's perfectly possible to apply our product just after a laser session, when the skin is still inflamed, for several reasons:Formula sterility:

The product is sterile, which considerably reduces the risk of infection. After laser treatment, the skin is more vulnerable to infection due to its compromised surface. A sterile product ensures that no pathogens are introduced, enabling safe application to open wounds or recently treated areas, promoting clean, uncomplicated healing.

Anti-inflammatory properties of tranexamic acid: Tranexamic acid exhibits anti-inflammatory properties by acting on the vascular and pigment pathways, helping to reduce inflammation and redness immediately after laser treatment. Unlike other depigmenting agents, which often target only the pigment pathway (tyrosinase), it also helps reduce the risk of HPI.

Niacinamide properties: Niacinamide acts effectively as a potent inhibitor of pro-inflammatory cytokines, helping to reduce inflammation. It also has significant depigmenting properties thanks to its inhibitory action on tyrosinase. This dual action enables significant synergies with TXA, reinforcing both the treatment of the pigmentary pathway and the anti-inflammatory effect on the vascular/plasminogenic pathway.

Post-laser application recommendations: We recommend applying our product topically (without microneedling) just after a laser session (or any other procedure at risk of IPH: laser, LED, injection, peel...). The combination of 5% TXA and 10% NIA amplifies results on spot treatment (if the laser is intended to treat spots) and limits the risk of post-inflammatory hyperpigmentation.

Yes, you can combine these 2 procedures. When our product is applied by microneedling, it only reaches the epidermis and superficial dermis (between 0.7 mm and 1.5 mm deep), without penetrating the deep dermis. This means that our TXA will not react with the area treated by HIFU, which is much deeper.

We carried out a clinical study with 4 microneedling sessions over a 49-day period on a panel of 100% sensitive skin with melasma and lentigos. The results showed very good tolerance in 100% of subjects. Our clinical study also demonstrated the efficacy of the procedure, with results showing a reduction in spot size of up to 73.9% after 49 days.